NEW YORK, NY / ACCESSWIRE / August 10, 2022 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GSK plc (GSK) ('GSK' or the 'Company') (NYSE:GSK). Investors who purchased GSK securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/gsk.

The investigation concerns whether GSK has violated federal securities laws.

On August 9, 2022, Vir Biotechnology, Inc. ('Vir'), GSK's development partner for the proposed COVID-19 treatment sotrovimab, issued a press release disclosing that that Vir 'and GSK do not plan to file a Biologics License Application for sotrovimab at this time and do not intend to pursue the US-based Phase 3 COMET-STAR prophylaxis trial. Discussions with the FDA remain ongoing regarding the appropriate path forward for sotrovimab in the US.' On this news, GSK's American Depositary Receipt price fell sharply during intraday trading on August 10, 2022.

If you are aware of any facts relating to this investigation or purchased GSK shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/gsk. You can also contact Peretz Bronstein or his Law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]

SOURCE: Bronstein, Gewirtz and Grossman, LLC